Combinatorial therapy for attenuating prostate cancer bone metastasis: A pharmaceutical mixture encompassing  Simvastatin and Navitoclax (SAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 3/March/2019, 8.33 am